Management of direct antiviral agent failures
María Buti, Rafael Esteban
Clin Mol Hepatol. 2016;22(4):432-438.   Published online 2016 Dec 25     DOI: https://doi.org/10.3350/cmh.2016.0107
Citations to this article as recorded by Crossref logo
Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes
Vanessa D. Costa, Carlos E. Brandão-Mello, Estevão P. Nunes, Pedro Guilherme Corôa dos Santos Silva, Lia Laura Lewis Ximenez de Souza Rodrigues, Elisabeth Lampe, Francisco Campello do Amaral Mello, Tatsuo Kanda
PLOS ONE.2019; 14(5): e0216327.     CrossRef
Tolerability and effectiveness of generic direct‐acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients
Sameh A. Lashen, Mohammed M. Shamseya, Marwa A. Madkour, Galal A. Aboufarrag
Liver International.2019; 39(5): 835.     CrossRef
Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1
Vanessa Duarte Costa, Nathália Delvaux, Carlos Eduardo Brandão-Mello, Estevão Portela Nunes, Paulo Sérgio Fonseca de Sousa, Lia Laura Lewis Ximenez de Souza Rodrigues, Elisabeth Lampe, Francisco Campello do Amaral Mello
Clinics and Research in Hepatology and Gastroenterology.2019;[Epub]     CrossRef
Human-rat chimeric anti-occludin monoclonal antibodies inhibit hepatitis C virus infection
Yoshimi Shimizu, Kohei Yoneda, Yoshitaka Shirasago, Takeru Suzuki, Minoru Tada, Akiko Ishii-Watabe, Kazuo Sugiyama, Tetsuro Suzuki, Takaji Wakita, Kiyohito Yagi, Masuo Kondoh, Masayoshi Fukasawa
Biochemical and Biophysical Research Communications.2019; 514(3): 785.     CrossRef
Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases
S. Miuma, H. Miyaaki, Y. Miyazoe, T. Suehiro, R. Sasaki, H. Shibata, N. Taura, K. Nakao
Transplantation Proceedings.2018; 50(1): 222.     CrossRef
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed Zanaty, Mohamed Ramadan
Digestive Diseases and Sciences.2018; 63(5): 1341.     CrossRef
A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed I. Zanaty, Mohamed Ramadan
Journal of Hepatology.2018; 68(6): 1313.     CrossRef
New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials
Valentina Pecoraro, Rita Banzi, Elisabetta Cariani, Johanna Chester, Erica Villa, Roberto D'Amico, Vittorio Bertele', Tommaso Trenti
Journal of Clinical and Experimental Hepatology.2018;[Epub]     CrossRef
The outcome of combined treatment with ombitasvir-paritaprevir-ritonavir, sofosbuvir with or without ribavirin as salvage therapy for Egyptian HCV experienced patients: A single center study
Waleed Abdelfattah Ismail, Fady Maher Wadea
Drug Discoveries & Therapeutics.2018; 12(6): 368.     CrossRef
Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4+ T cells contributes to viral persistence in chronic hepatitis C
Ya Zhuo, Yi-Fu Zhang, Hong-Jie Wu, Lei Qin, Yan-Ping Wang, A-Min Liu, Xin-Hong Wang
Biomedicine & Pharmacotherapy.2017; 94: 386.     CrossRef
Treatment of Chronic Hepatitis C Patients Who Do Not Respond to Direct Acting Antivirals
Jeong Han Kim
The Korean Journal of Gastroenterology.2017; 70(2): 111.     CrossRef
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection
Nancy Reau, Michael N. Robertson, Hwa-Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach-Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer
Hepatology Communications.2017; 1(8): 757.     CrossRef
Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030
Mark W Sonderup, Mary Afihene, Reidwaan Ally, Betty Apica, Yaw Awuku, Lina Cunha, Geoffrey Dusheiko, Neliswa Gogela, Marie-Jeanne Lohouès-Kouacou, Phillip Lam, Olufunmilayo Lesi, Papa Saliou Mbaye, Emmanuel Musabeyezu, Betty Musau, Olesegun Ojo, John Rweg
The Lancet Gastroenterology & Hepatology.2017; 2(12): 910.     CrossRef
Retreatment Options Following HCV Direct-Acting Antiviral Failure
Autumn Zuckerman, Cody A. Chastain, Susanna Naggie
Current Treatment Options in Infectious Diseases.2017; 9(4): 389.     CrossRef
Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles
Longbo Hu, Jinqian Li, Hua Cai, Wenxia Yao, Jing Xiao, Yi-Ping Li, Xiu Qiu, Huimin Xia, Tao Peng
Antiviral Research.2017; 148: 5.     CrossRef